You are here

  • Home
  • Archive
  • Volume 13, Issue 1
  • Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

Article Text

Article menu
Download PDFPDF
Letter
Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic
  1. John McGoran1,
  2. Alan Wilson2,
  3. Shannan McErlain2,
  4. Noreen Kennedy1,
  5. Caroline Masterson1,
  6. Caroline Collins1,
  7. Graham Morrison1
  1. 1 Gastroenterology, Belfast Health and Social Care Trust, Belfast, UK
  2. 2 Pharmacy, Belfast Health and Social Care Trust, Belfast, UK
  1. Correspondence to Dr Graham Morrison, Gastroenterology, Belfast Health and Social Care Trust, Belfast BT13 1FD, UK; graham.morrison{at}belfasttrust.hscni.net

https://doi.org/10.1136/flgastro-2020-101760

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Promising evidence in the subcutaneous (SC) administration of the infliximab (IFX) biosimilar CT-P13 (Remsima) has emerged in recent years. Furthermore, immunogenicity data have suggested superior steady state therapeutic blood levels of IFX and lower rate of anti-IFX antibodies in a cohort of patients receiving SC Remsima following two intravenous induction doses in contrast to their counterparts who continued to receive intravenous therapy.1 2 In response to the challenges posed by the COVID-19 pandemic to patients with inflammatory bowel disease (IBD) receiving IFX, we embarked on a patient-partnered programme in switching to SC Remsima. Seventy-five individuals were included in the preliminary service development and some demographics are outlined in table 1. An assessment of patients’ attitudes was conducted using a survey.

    View this table:
    • In this window
    • In a new window
    Table 1

    Demographic …

    View Full Text

    Footnotes

    • Contributors JMG is lead author and designed the patient survey. AW led the initial service improvement and contributed to the article. SME supported the service development and contributed to the article. NK supported the service development and contributed to the article. CM supported the service development and contributed to the article. CC supported the service development and contributed to the article. GM was clinical lead for service development and is senior author.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.